-
4 innovative pharmaceutical companies completed financing of more than 100 million yuan to promote the research and development of new drugs
Time of Update: 2022-01-10
Recently, four Chinese innovative pharmaceutical companies announced that they have completed financing of more than 100 million yuan to promote the research and development of innovative double-antibody and polyclonal drugs, and the research and development of AI+RNA drugs .
-
Innovative drugs introduced by CMS for the treatment of psoriasis are planned to be included in the priority review
Time of Update: 2022-01-10
ArticleMedicine GuanlanAccording to the latest announcement by the Center for Drug Evaluation (CDE) of the National Medical Products Administration of China, the methotrexate injection (prefilled) introduced by CMS is based on “the innovation of urgently needed clinically-needed drugs, imitation of key infectious diseases, rare diseases and other diseases.
-
Pharmaceutical companies talk about how to plan insulin in the post-centralized procurement era
Time of Update: 2022-01-10
The author was informed that, in addition to Ganli Pharmaceutical's disclosure of the company's plans for insulin in the post-centralized procurement era, Tonghua Dongbao also stated that it will deepen its efforts in the endocrine field and increase its deployment of innovative drug R&D pipelines .
-
Conversion of a single oral formulation of dextromethorphan hydrobromide to a prescription drug
Time of Update: 2022-01-10
2. After the supplementary application for the modification of the instructions for this product is approved, the holder of the drug marketing authorization of the relevant product shall replace the instructions and labels of the medicines that have been shipped out of the factory within 9 months, and shall collect and report adverse reaction information in a timely manner.
-
The pharmaceutical company was fined 300,000 yuan for stepping on the "red line" of the advertisement
Time of Update: 2022-01-10
For example, in August 2020, Yaben Chemical responded to investors’ questions on the interactive platform of the Shenzhen Stock Exchange about whether the company produces pharmaceutical intermediates for antiviral drugs related to the pneumonia epidemic.
-
34 drug operating companies meet or basically meet GSP compliance supervision and inspection
Time of Update: 2022-01-10
and 34 pharmaceutical companies have carried out drug management quality management standards ( GSP) conformity supervision and inspection, and the comprehensive assessment conclusions are in conformity and basic conformity are announced .
Serial number company name drug business license inspection time comprehensive evaluation conclusion 1 Guangdong Yuekang Pharmaceutical Co.
-
The tens of billions of oral hypoglycemic drugs market has new competitors entering the market
Time of Update: 2022-01-10
In addition, on January 21, the State Food and Drug Administration public information showed that Hunan Qianjin Xiangjiang Pharmaceutical's acarbose tablets were approved for production in four types of imitations, and they were deemed to have been reviewed .
-
Competition in the pharmaceutical equipment industry continues to intensify, how to break through in the future?
Time of Update: 2022-01-10
In addition, in terms of internationalization, as competition in the pharmaceutical equipment market continues to intensify, the quality and technology of local companies continue to improve, and the demand for overseas markets continues to increase, the international layout has already become a major development in China’s pharmaceutical equipment industry.
-
With the help of policies, high-end medical equipment ushered in new opportunities for development
Time of Update: 2022-01-10
In recent years, the country has actually been vigorously supporting the development of domestic high-end medical equipment, and has successively introduced a series of industry-related policies to actively guide government units and medical and health institutions to use domestically produced equipment and promote the domestic substitution of high-end equipment .
-
Fosun Pharma terminates Phase I clinical and follow-up development of SGLT-2 inhibitors
Time of Update: 2022-01-09
Article source: Medical Rubik's Cube InfoOn December 28, Fosun Pharma issued an announcement stating that its subsidiary, Jiangsu Wanbang, had decided to terminate the clinical trial and subsequent development of the SGLT-2 inhibitor vanagliflozin .
-
The development of the Internet medical industry is accelerating, and the influx of capital is accelerating
Time of Update: 2022-01-09
In addition, Internet medical-related companies such as WeDoctor, DingDang Health, Zhiyun Health, Supai Health, Yuanxin Technology, Keya Medical, and Shukun Technology have also submitted prospectuses to the Hong Kong Stock Exchange .
-
Innovative oral drug Phase III study failed BridgeBio's share price fell 72%
Time of Update: 2022-01-09
In the ATTribute-CM study, key clinical data for 632 patients showed that the average decrease in 6-minute walk distance (6MWD) observed in the acoramidis group and placebo group at the 12th month was 9 meters and 7 meters, respectively .
-
Recommended by exhibitors of the 2022 Old Fair, Xinjiang Asmail Elderly Goat Milk Powder and Camel Milk Powder
Time of Update: 2022-01-09
Mainly exhibited products: goat milk powder, camel milk powder Xinjiang Asmail Dairy Co.
Focusing on the research and development and production of goat milk powder, camel milk powder and other specialty dairy products, it has now developed into a leading agricultural industrialization enterprise in Xinjiang Autonomous Region that integrates product research and development, dairy production, marketing, and consulting services .
-
Two medical device registration certificates including electronic sigmoid colonoscopy were cancelled
Time of Update: 2022-01-09
On December 28, the State Food and Drug Administration issued an announcement stating that, in accordance with the provisions of the Regulations on the Supervision and Administration of Medical Devices, the registration of individual products of two companies including Yingshi (Guangzhou) Special Equipment Manufacturing Co.
-
Nuocheng Jianhua TYK2 JH2 allosteric inhibitor new drug research application was accepted by the State Food and Drug Administration
Time of Update: 2022-01-09
On December 28, Nuocheng Jianhua announced that the company's self-developed TYK2 JH2 allosteric inhibitor ICP-488 New Drug Research (IND) application has been accepted by the National Medical Products Administration (NMPA) .
Factor-driven cell signal transduction, thereby inhibiting the pathological process of autoimmunity and inflammation .
-
More than 20 new drugs passed the consistency evaluation within one week
Time of Update: 2022-01-09
The third-generation quinolone antibiotic norfloxacin capsules of the Baiyunshan branch company's Baiyunshan Pharmaceutical General Factory have recently passed the consistency evaluation of generic drugs .
The company declared the consistency evaluation of the quality and efficacy of generic drugs in March 2020, and was approved recently .
-
Comparing the performance of pharmaceutical equipment companies in 2021, leading companies have achieved steady growth
Time of Update: 2022-01-09
On the evening of October 28, Tailin Biotechnology released its third quarter report for 2021, stating that the company’s main operating income was 182 million yuan, a year-on-year increase of 36.
-
2022 Barrier-free Facilities Exhibition China Shandong International Disabled Rehabilitation Exhibition
Time of Update: 2022-01-09
Comprehensively display the latest products and services of rehabilitation equipment, rehabilitation engineering, barrier-free facility renovation, supplies for the disabled, home care, family medical care and other industries, strengthen technical exchanges and economic and trade cooperation between domestic and foreign enterprises, build a new development pattern, and promote the disabled The upstream and downstream industrial chains of the rehabilitation industry are effectively connected and developed with high quality .
-
Beijing: Another 74 innovative drugs will be included in medical insurance reimbursement from next year
Time of Update: 2022-01-09
71%; newly included medicines complement the demand for drugs for tumors, chronic diseases, anti-infections, and rare diseases Recently, the Beijing Municipal Medical Insurance Bureau and the Municipal Human Resources and Social Security Bureau jointly issued a notice to include 74 innovative drugs such as Noxinassen Sodium Injection in the scope of reimbursement for Beijing’s medical insurance, with an average decrease of 61.
-
Under the acceleration of innovation and upgrading by domestic pharmaceutical companies, many new drugs have been introduced
Time of Update: 2022-01-09
In addition to Tasly, BeiGene also announced on December 14 that it had signed a cooperation with Wei Li Zhibo, from the latter to introduce a global research and development and production license for the LAG-3 antibody LBL-007, and Exclusive commercialization rights outside of China .
